Shanghai Xiao Fang Pharmaceutical Co.,Ltd. (SHA:603207)

SHA:603207 Revenue

Shanghai Xiao Fang Pharmaceutical had revenue of 143.97M CNY in the quarter ending September 30, 2026, with 12.98% growth. This brings the company's total for the last twelve months to 553.96M, up 9.78% year-over-year. In the year 2025, Shanghai Xiao Fang Pharmaceutical had annual revenue of 525.28M with 10.68% growth. That makes Shanghai Xiao Fang Pharmaceutical the 24,132nd largest company in the world by revenue and 4,337th in China.

• Revenue (ttm): 553.96M
• Revenue Growth: +9.78%
• P/S Ratio: 6.50
• Revenue / Employee: 1.05M
• Employees: 529
• Market Cap: 3.60B

Revenue Chart

Chart

Chart

Revenue by Geography

Chart

• East China 182.77M 34.8%
• South China 85.52M 16.3%
• North China 69.59M 13.3%
• Southwest 59.12M 11.3%
• Central China 58.87M 11.2%
• Northeast 45.23M 8.6%
• Northwest 23.40M 4.5%
• Overseas 210.42K 0.0%

Fiscal year ended Dec 31, 2025 See the full SHA:603207 breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	525.28M	50.70M	10.68%
Dec 31, 2024	474.58M	2.71M	0.57%
Dec 31, 2023	471.87M	14.98M	3.28%
Dec 31, 2022	456.89M	55.12M	13.72%
Dec 31, 2021	401.77M	40.54M	11.22%

Data Source: S&P Global Market Intelligence Last updated: Oct 23, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 10, 2026

Data Sources Report a data error